BIOMIMESYS® Biofunctionalized hydroscaffold for 3D cell culture

•

1 recomendación•1,530 vistas

To better mimic the tissue microenvironment and provide more predictive tools for drug development. hello@biominesys.com

Atención sanitaria

To better mimic the tissue
microenvironment and provide more
predictive tools for drug development
BIOMIMESYS®
Biofunctionalized hydroscaffold
for 3D cell culture
Biotechnology company specialized in cell imaging
which provides HCA/HCS services
BIOMIMESYS® ScaffoldDecellularized in vivo ECM
by

Product
Specifications Compositions
Elastic
modulus
BIOMIMESYS®
Liver
HA + RGDS, Galactosamine,
Collagen I, Collagen IV
0.6 kPa
BIOMIMESYS®
Adipose tissue
HA + RGDS, Collagen I,
Collagen VI
0.45 kPa
BIOMIMESYS®
Oncology
HA + Collagen I 0.4 kPa
Plate specifications:
 RGDS or Galactosamine grafted
Hyaluronic Acid
 Physiological amount of ECM
compound
 Undenatured collagen
 Elastic modulus regarding organs
Scalable hydroscaffold
in vivo like chemical composition and physicochemical
properties (porosity , Elastic modulus...)
BIOMIMESYS® hydroscaffold
Precast matrix in a 96-WELL PLATE
The only technology based on HA and ECM compound
ready to use

Cell lines
Primary cells
iPSCs
e.g. HepG2
3 – CHOOSE YOUR READ-OUTS
Hoechst ; EDU;
mitotracker; colocalization
HCT116
Proliferation, apoptosis, cell motility, Cell structure, Stress, Protein
analysis, mRNA analysis …
MRP2; Actin;
colocalization
HepG2
1 – CHOOSE YOUR CELLS & MICROENVIRONNEMENT
2 - CHOOSE YOUR INDUCERS & INCUBATION TIME
Services
ECM: Define
- Composition
- Elastic modulus
- Porosity
Perilipin (TG), nucleus
Human Preadipocytes
(HWP)
Small
Molecules
Biologicals Ingredients Starvations
UV
Radiations
Fixed
Cells
Live
Cells
BIOMIMESYS® Liver
Hoechst; Phalloidin
HepG2
BIOMIMESYS®
Adipose Tissue
BIOMIMESYS®
Oncology

Contact us for further information
www.biomimesys.com
hello@biomimesys.com
+33 769 999 137
Lille Rennes
OUR VALUES  Expertise
 Efficiency
 Flexibility
 Transparency
Robotic Platform & innovative 3D models
for HCA and HCS services
Innovative & relevant in vitro
models
Enriched information on biological
content
Phenotypic screening
Highly visual
Automated process
Multi-parametric study
Big Data / Machine learning

Más contenido relacionado

Más de HCS Pharma

Poster HCSPHARMA (OncoLilleDays2022) - Mechanobiological characterization of ...

HCS Pharma

Abstract: Lung cancer is one of the most frequent cancers in the world with a high mortality rate. The discovery of oncogenic alterations in these cancers allowed the development of targeted therapies against several receptor tyrosine kinases (RTK) including EGFR, ALK or MET and contributed to improve the prognosis of some patients. Mutations impacting the MET receptor exon 14 splice sites (METex14) have recently been detected in about 3% of lung cancers and lead to the loss of the juxtamembrane domain with several negative regulatory sites. METex14 does not lead to constitutive activation of the receptor but we demonstrated that HGF, its ligand, is required for the full development of the transforming capabilities of the METex14 receptor in SCID-HGFhuman transgenic mice. Several clinical trials have shown that only half of METex14 patients responded to MET inhibitors. While encouraging, these results are lower than those obtained with other treatments such as EGFR inhibitors. Interestingly, METex14 mutations are frequently associated with other molecular alterations including PTEN loss or TP53 mutations. Furthermore, we have shown that many METex14 mutated patients have autocrine secretion of HGF ligand. Understanding how these co-alterations impact METex14 oncogenicity and sensitivity to existing therapies is of outmost importance to identify patients that could benefit from them.

Poster : Development of personalized therapeutic targeting in lung cancer wit...

HCS Pharma

In oncology, 97% of drug candidates fail in clinical trials. This highlights a lack of relevance of preclinical models used upstream. Indeed, human in vitro models don’t consider the Tumoral Extracellular Matrix (TECM). However, more and more studies demonstrate that ECM composition and stiffness are modified in tumors and are linked to cancer initiation, progression, propagation, and drug resistances. BIOMIMESYS® is a Hyaluronic Acid-based matrix grafted with structural and adhesion molecules, which mimics the ECM/TECM. It is chemically defined and its composition and stiffness can be modified to reproduce the organ-specificity of the ECM, or to mimic a pathological microenvironment in vitro. We have demonstrated that the exposition of colon cancer cells cultured in BIOMIMESYS® Oncology matrix to an anti-proliferative drug showed a closer in vitro/in vivo correlation in the EC50 curve compared to 2D culture. Cancer cells can be advantageously grown in BIOMIMESYS® for several weeks in multiwell plates and in microfluidic chips for more advanced models. We also observed that modifications in the matrix composition and stiffness modify the cell behavior. Moreover, thanks to collaborations with academic laboratories, we demonstrated that BIOMIMESYS® allows to reproduce in vitro the behavior of cancerous cells in vivo, like mutation effects and metastasis propagation, and could be a relevant alternative to animal models. These results showed that the matricial microenvironment modifies the cell behavior in vitro and should be considered carefully in drug discovery. BIOMIMESYS® hydroscaffold™ is adapted to High Content Screening and represented a powerful tool to better select drug candidate.

Poster - Including the matricial tumoral microenvironment in 3D in vitro mode...

HCS Pharma

We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to study metabolic diseases upon hepatocyte-like cell (HLC) differentiation. With a non-invasive approach, hiPSCs can be generated from urine samples of patients and HLCs have been used to model cholesterol metabolism regulation, by the study of LDLR- and PCSK9-mediated autosomal dominant hypercholesterolemia (ADH) as well as PCSK9-mediated familial hypobetalipoproteinemia (FHBL). This model provides promising advantages with a direct link to the patient and with an unlimited source of HLCs. But like all models, there are limitations, mainly by the neonatal characteristic of HLCs lead to difficulties for pharmacological investigations.   Therefore, to overcome these burdens, we chose to 1. Differentiate hiPSCs into HLCs in an innovative 3D <a href="https://hcs-pharma.com/biomimesys/">hyaluronic acid-based hydroscaffold</a>, BIOMIMESYS® produces by HCS Pharma to enhance their maturation. 2. Adapt our 3D differentiation process to a 96-well format to make it compatible for drug screening. 3. Characterization of the 3D HLCs model by metabolism tests and compare to primary human hepatocyte (PHH).   We gathered 3’ SRP data all along the differentiation process and RNAseq has been performed by comparing 2D and 3D differentiation conditions to characterize hiPSCs differentiation into liver organoids. We observed an enhanced expression of most hepatic genes and genes expressed by non-parenchymal cells such as stellate cells. Immunofluorescence data confirmed the co-localization of albumin-positive hepatocytes, desmin-positive stellate cells and LYVE1-positive endothelial cells in liver organoids. Finally, at a functional level, several CYP activities including CYP3A4 were detected at the basal level and successfully induced. Liver organoids responded to pharmacological treatments as shown by their ability to accumulate lipids upon amiodarone treatment or uptake LDL-bodipy upon statin treatment.   Altogether, our development gave rise to functional liver organoids generated with a unique and common procedure, in a process of automating for future high throughput screening.

HCS PHARMA - (ECM 2022) Development of innovative hiPSC-based model including...

HCS Pharma

Aim: About 90% of drug-candidates failed in clinical trials, in particular in neurology, due to a lack of efficacy. That highlights a lack of relevance in preclinical models, including in vitro models, which do not take into account the microenvironment, composed by glial cells and the Extracellular Matrix (ECM). The objective was to study the influence of the microenvironment in cerebral in vitro models, in the frame of Parkinson’s Disease (PD). Methods: First, we analyzed the influence of astrocytes on Luhmes cell sensitivity, a dopaminergic neuronal cell line, in 2D culture. Then, we developed a hyaluronic acid-based hydroscaffold for 3D cell culture, which mimics the ECM, and study the sensitivity of Luhmes cells in this model. Thirdly, we performed a co-culture of Luhmes cells and astrocytes in this matrix, to form a complex model including both the glial and the matricial microenvironments. Results: We observed a protective effect of astrocytes in 2D culture. In the hydroscaffold, Luhmes cells displayed a lower sensitivity compared to 2D culture, that was explained by a partial retention of toxic molecules in the matrix, and differences in neuronal protein expression. In the co-culture, we observed spheroids containing both neurons and astrocytes. Conclusions: This work highlighted that the microenvironment of neurons can modify the neuronal response in vitro, and should thus be considered carefully in academic research and in drug discovery. This model can be now used to study the microenvironment modifications in pathological conditions, and to develop innovative drugs targeting the microenvironment.

HCSPHARMA Importance of microenvironment in cerebral in vitro models for phen...

HCS Pharma

metabolic diseases upon hepatocyte-like cell (HLC) differentiation. In particular, HLCs have been used to model cholesterol metabolism regulation, by mimicking the main disease features in vitro. Human iPSCs can be generated from urine samples of patients with a well-described phenotype and carrying specific genotypes. This non-invasive approach allowed the study of LDLR- and PCSK9-mediated autosomal dominant hypercholesterolemia (ADH) as well as PCSK9-mediated familial hypobetalipoproteinemia (FHBL). While the direct link between hiPSCs and patients, as well as the abundance of HLCs provide promising advantages of such strategy, it is impaired mainly by the neonatal characteristic of HLCs as well as the difficulty to perform high throughput studies for pharmacological investigations.

Poster - A single procedure to generate functional hiPSCs-derived liver organ...

HCS Pharma

There is a 90% failure in clinical trials, due to efficacy and safety issues, which frequently concerns the central nervous system. That points a lack of relevance of preclinical models used upstream. In this frame, the aim of this study was to develop more relevant cerebral in vitro models, by including the matricial and cellular microenvironments, for drug discovery in Parkinson's disease. HD available on https://hcs-pharma.com/poster---importance-of-matricial-and-cellular-microenvironments-in-in-vitro-models-for-drug-discovery-in-parkinsons-disease/

Importance of matricial and cellular microenvironments in in vitro models for...

HCS Pharma

Growing interest in phenotypic screening, together with evidence that the drug response of cells grown in three-dimensional (3D) structures more closely resembles in vivo activity, has made high throughput, 3D fluorescence imaging an attractive screening option for drug discovery. However, creating 3D spheroids compatible with high content screening can be a difficult and expensive process. BIOMIMESYS® is a range of patented hyaluronic acid scaffolds for 3D cell culture. They are made of RGDS- and galactosaminegrafted hyaluronic acid, using an adipic acid dihydrazide crosslinker and extracellular matrix proteins (eg. type I, IV or VI collagen) to accurately mimic the in vivo extracellular environment. BIOMIMESYS® is suitable for automated testing thanks to the uniform thickness of the scaffold – around 650 μm – with an average porosity of 100 to 200 μm This application note describes a straightforward workflow for 3D cell seeding and spheroid formation using HCS Pharma’s BIOMIMESYS® plates in combination with INTEGRA’s VIAFLO 96/384 pipetting system. This process ensures rapid, controllable and reproducible 3D cell cultures, providing researchers with a highly efficient method to produce physiologically-relevant cellular models in a high throughput format

Simplifying 3d cell culture generation for high content screening with BIOMIM...

HCS Pharma

BIOMIMESYS® range are hyaluronan based hydroscaffold developed to overcome the 2D flat culture limitations by recreating an in vivo-like physiology within the in vitro environment. BIOMIMESYS®Liver hydroscaffold is made of RGDS and galactosamine-grafted Hyaluronic acid, Adipic acid dihydrazide crosslinker and extracellular matrix (ECM) proteins (collagen type I and collagen type IV) to mimic liver ECM composition.

BIOMIMESYS®Liver, a 3D cell culture model for maintaining and promoting hepat...

HCS Pharma

Abstract : a single procedure to generate functional hi ps cs-derived liver o...

HCS Pharma

Poster – Development and automation of 3D innovative hiPSC-based liver organo...

HCS Pharma

Poster – Development and automation of 3D innovative hiPSC-based liver organo...

HCS Pharma

Development of a new liver-on-chip including BIOMIMESYS® technology for mimic...

HCS Pharma

HCS Pharma complète sa gamme de culture cellulaire en 3D BIOMIMESYS® avec BIO...

HCS Pharma

We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to study metabolic diseases upon hepatocyte-like cell (HLC) differentiation. In particular, HLCs have been used to model cholesterol metabolism regulation, by mimicking the main disease features in vitro. Human iPSCs can be generated from urine samples of patients with a well-described phenotype and carrying specific genotypes. This non-invasive approach allowed the study of LDLR- and PCSK9-mediated autosomal dominant hypercholesterolemia (ADH) as well as PCSK9-mediated familial hypobetalipoproteinemia (FHBL). While the direct link between hiPSCs and patients, as well as the abundance of HLCs provide promising advantages of such strategy, it is impaired mainly by the neonatal characteristic of HLCs as well as the difficulty to perform high throughput studies for pharmacological investigations. Therefore, to overcome these burdens, we choose to 1. Differentiate hiPSCs into HLCs in a 3D environment instead of the classical 2D culture systems to enhance their maturation; 2. Adapt our 3D differentiation process to a 96 wells format to make it compatible for drug screening. To reach our goals, we established a partnership with HCS Pharma, which has an expertise in high content phenotypic screening and produces an innovative 3D scaffold, BiomimesysTM. This scaffold is composed of hyaluronic acid that can be functionalized with extra cellular matric derivatives, with adjustable stiffness and porosity. We setup conditions for hiPSCs seeding and differentiation to reach a new protocol adapted to a 3D environment. Our preliminary data indicate that our procedure enhanced expression of hepatic markers such as transcription factors (FOXA2, FOXA3, HNF1a, HNF1b, HNF4a), cytochrome P450 (CYP450) family members (CYP3A4, CYP2A6, CYP7A1) or cholesterol metabolism regulators (PCSK9, Lipoprotein(a)). During our presentation, we will discuss our data hiPSCs differentiation in 3D, CYP450 activities and induction, as well as their application for the study of metabolic diseases.

3D innovative hiPSC-based models including the microenvironment for phenotyp...

HCS Pharma

As shown by AstraZeneca in Nature reviews*, one third of the safety failures is linked to CNS toxicity during the clinical trials of drugs. Therefore, relevant in vitro human model is needed to detect early neurotoxicity of drug candidates. In this study, sensitivity of iPSC-derived neuronal cells to 32 compounds is compared to the sensitivity of SH-SY5Y cells. Two types of iPS-derived cells are tested: central nervous system cells (CNS.4U™ cells) and peripheral nervous system cells (PERI.4U™ cells) from Ncardia. Toxic effects are then measured by HCS cell imaging.

Neurotoxicity assessment: Comparison between SH-SY5Y and iPSC-derived cells

HCS Pharma

BIOMIMESYS® range are hyaluronan based scaffolds developed to overcome the 2D flat culture limitations by recreating an in vivo physiology within the in vitro environment. BIOMIMESYS® Adipocyte scaffold is made of RGDS-grafted Hyaluronic acid (1.6 MDa), Adipic acid dihydrazide crosslinker and extracellular matrix (ECM) proteins (collagen type I and collagen type VI) to mimic fat tissue-ECM composition.

BIOMIMESYS® Adipose tissue, a relevant in vitro adipocyte 3D model

HCS Pharma

BIOMIMESYS® range are hyaluronan based hydroscaffold developed to overcome the 2D flat culture limitations by recreating an in vivo-like physiology within the in vitro environment. BIOMIMESYS®Liver scaffold is made of RGDS and galactosamine-grafted Hyaluronic acid, Adipic acid dihydrazide crosslinker and extracellular matrix (ECM) proteins (collagen type I and collagen type IV) to mimic liver-ECM composition.

BIOMIMESYS® Liver, a 3D cell culture model for maintaining and promoting hep...

HCS Pharma

HCS for brain disorders / HCS Pharma at B4B mars 2018

HCS Pharma

La société HCS Pharma, spécialiste de l’imagerie cellulaire à haut débit et du développement de nouveaux modèles cellulaires, est née à Rennes (35) en août 2014. Le 6 octobre dernier, elle a inauguré de nouvelles installations à Lille (59), au cœur du parc Eurasanté, et y a mis à l’honneur notamment sa toute nouvelle plate-forme robotique baptisée HAPIx, HCS Automation Platform for Imaging. Nathalie MAUBON, Présidente de l’entreprise, nous présente HCS Pharma et ses nouvelles ambitions portées par cette implantation lilloise, au plus proche des chercheurs et cliniciens en santé humaine...

Présentation de HCS Pharma dans la gazette du laboratoire - 2017

HCS Pharma

Más de HCS Pharma (20)